{"id":"gardasil-as-three-dose-regimen","safety":{"commonSideEffects":[{"rate":"48-78","effect":"Injection site pain, swelling, or erythema"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Myalgia"},{"rate":"1-3","effect":"Fever"},{"rate":"5-10","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1231533","moleculeType":"Small molecule","molecularWeight":"285.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains virus-like particles (VLPs) derived from the major capsid protein (L1) of four HPV types. When administered, these VLPs trigger a humoral immune response that generates neutralizing antibodies against HPV, preventing infection and subsequent development of HPV-related diseases. The three-dose regimen is designed to achieve optimal immunogenicity and long-term protection.","oneSentence":"Gardasil is a recombinant quadrivalent human papillomavirus (HPV) vaccine that stimulates the immune system to produce antibodies against HPV types 6, 11, 16, and 18.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:42.799Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of cervical cancer caused by HPV types 16 and 18"},{"name":"Prevention of genital warts caused by HPV types 6 and 11"},{"name":"Prevention of anal cancer and other HPV-related malignancies"}]},"trialDetails":[{"nctId":"NCT04982614","phase":"PHASE4","title":"HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini","status":"COMPLETED","sponsor":"Columbia University","startDate":"2022-04-01","conditions":"HPV Infection, Hiv, HPV Vaccine","enrollment":1403},{"nctId":"NCT06281119","phase":"PHASE3","title":"Clinical Study to Evaluate SIIPL QHPV Vaccine (CERVAVAC®) in Women Living with HIV Aged 15-25 Years","status":"NOT_YET_RECRUITING","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2025-03","conditions":"Human Papillomavirus Infection","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Gardasil as three dose regimen","genericName":"Gardasil as three dose regimen","companyName":"Serum Institute of India Pvt. Ltd.","companyId":"serum-institute-of-india-pvt-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Gardasil is a recombinant quadrivalent human papillomavirus (HPV) vaccine that stimulates the immune system to produce antibodies against HPV types 6, 11, 16, and 18. Used for Prevention of cervical cancer caused by HPV types 16 and 18, Prevention of genital warts caused by HPV types 6 and 11, Prevention of anal cancer and other HPV-related malignancies.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}